{
    "nct_id": "NCT02905188",
    "official_title": "Glypican 3-specific Chimeric Antigen Receptor Expressing T Cells As Immunotherapy for Patients with Hepatocellular Carcinoma",
    "inclusion_criteria": "* Histology-proven hepatocellular carcinoma (HCC) which is unresectable, recurrent and/or metastatic\n* Barcelona Clinic Liver Cancer Stage A, B or C\n* GPC3-positive HCC\n* Age ≥ 18 years\n* Karnofsky score ≥ 60% (See appendix I)\n* Life expectancy ≥ 12 weeks\n* Child-Pugh-Turcotte score <8\n* Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent\n\nExclusion Criteria\n\n* History of hypersensitivity reactions to murine protein-containing products OR presence of human anti-mouse antibody (HAMA) prior to enrollment (only patients who have received prior therapy with murine antibodies).\n* History of liver transplantation\n* Known HIV positivity\n* Active bacterial, fungal or viral infection (except Hepatitis B or Hepatitis C virus infections)\n* Severe previous toxicity from cyclophosphamide or fludarabine\n\nTreatment Eligibility\n\nInclusion Criteria:\n\n* Histology-proven hepatocellular carcinoma (HCC) which is unresectable, recurrent and/or metastatic\n* Barcelona Clinic Liver Cancer Stage A, B or C\n* GPC3-positive HCC\n* Age ≥ 18 years\n* Life expectancy of ≥ 12 weeks\n* Karnofsky score ≥ 60%\n* Child-Pugh-Turcotte score < 8\n* Adequate organ function:\n\n  * creatinine clearance (as estimated by Cockcroft Gault) ≥ 60 ml/min\n  * serum AST< 5 times ULN\n  * total bilirubin < 3 times ULN for age\n  * INR ≤1.7\n  * absolute neutrophil count > 500/microliter\n  * platelet count > 20,000/microliter (can be transfused)\n  * Hgb ≥7.0 g/dl (can be transfused)\n  * Pulse oximetry >90% on room air\n* Recovered from acute toxic effects of all prior antineoplastic drugs before entering this study (including investigational drugs) based on the enrolling physician's assessment (if some effects of chemotherapy are expected to last long term, patient is eligible if meeting other eligibility criteria).\n* Sexually active patients must be willing to utilize one of the more effective birth control methods for 3 months after the T-cell infusion.\n* Available autologous transduced T cell product\n* Informed consent explained to, understood by and signed by patient/guardian. Patient/guardian given copy of informed consent\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Eligible for complete tumor resection or liver transplantation.\n* Pregnancy or lactation (for women at child-bearing age, birth control is required)\n* Hepatic encephalopathy\n* Uncontrolled infection\n* Systemic steroid treatment (greater than or equal to 0.5 mg prednisone equivalent/kg/day)\n* Known HIV positivity\n* Active bacterial, fungal or viral infection (except Hepatitis B or Hepatitis C virus infections)\n* History of liver transplantation\n* Heart failure of Class III-IV and / or C-D per NYHA Criteria\n* History of hypersensitivity reactions to murine protein-containing products OR presence of human anti-mouse antibody (HAMA) prior to enrollment (only patients who have received prior therapy with murine antibodies)\n* Severe previous toxicity from cyclophosphamide or fludarabine",
    "miscellaneous_criteria": "Procurement Eligibility"
}